Rovi stock gains 1.20 percent as CDMO revenue jumps

Rovi stock (ISIN ES0157261019) was trading at EUR 58.85 on the Bolsa de Madrid on October 7, 2026 at 1:19 p.m. CEST, up 1.20 percent from the previous close. The move comes as the company reshapes its growth profile around contract manufacturing, specialty medicines and the Phoenix facility.

CDMO growth changes the mix

According to Yahoo Finance in its July 23, 2026 transcript, total first-half 2026 revenue rose 13 percent to EUR 357 million, while operating revenue increased 9 percent to EUR 344.2 million. CDMO revenue climbed 38 percent to EUR 106.3 million, giving the contract manufacturing division a larger role in the business mix.

Rovi reported first-half net profit of EUR 84.4 million, an increase of 113 percent from the same period of 2025. EBITDA reached EUR 121.2 million, although EBITDA excluding the EUR 62.4 million Phoenix acquisition badwill declined 10 percent to EUR 58.8 million.

Heparin remains the counterweight

The shift toward CDMO growth also highlights a weaker legacy area. The Objective reported on September 26, 2026 that heparin represented 38 percent of operating revenue in the first half, down from 43 percent a year earlier.

Heparin revenue fell 4 percent to EUR 130.1 million, while Okedi sales increased 27 percent to EUR 34 million in the same period, according to The Objective. The contrast matters because Rovi maintains its 2026 operating-revenue outlook at growth of 0 percent to 10 percent while partner inventories and pricing pressure weigh on heparins.

Analyst targets sit above price

Eulerpool lists a Buy consensus from 13 analysts as of February 1, 2026, alongside 3 Hold ratings and 0 Sell ratings. The average target is EUR 84.26, the median is EUR 85.07, and the published range runs from EUR 70.70 to EUR 96.60.

Against the EUR 58.85 Madrid price on October 7, 2026, the average analyst target lies 43.1 percent above the price. That gap gives the market a clear checkpoint, while the near-term operating picture depends on CDMO execution and the recovery of heparin demand.

November results set the next checkpoint

Rovi lists November 5, 2026 for its first nine months 2026 financial results. The publication will show whether Phoenix and CDMO growth continue to offset the pressure in heparins.

Rovi stock holds above EUR 58

Rovi stock was trading at EUR 58.85 on the Bolsa de Madrid on October 7, 2026 at 1:19 p.m. CEST, with a market capitalization of EUR 3.0 billion and a session range of EUR 58.00 to EUR 59.30.

Upcoming dates for Rovi stock

• November 5, 2026: First nine months 2026 financial results

More news and analyses on Rovi stock